Oncothyreon Inc . Rating Reiterated by Cantor Fitzgerald (ONTY)
Oncothyreon Inc . (NASDAQ: ONTY)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a report issued on Friday, TheFlyOnTheWall.com reports. They currently have a $4.00 target price on the stock.
Shares of Oncothyreon Inc . (NASDAQ: ONTY) traded up 0.68% during mid-day trading on Friday, hitting $2.225. Oncothyreon Inc . has a 52 week low of $1.71 and a 52 week high of $6.24. The stock’s 50-day moving average is currently $2.03. The company’s market cap is $127.2 million.
Oncothyreon Inc . (NASDAQ: ONTY) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. During the same quarter in the previous year, the company posted ($0.27) earnings per share. Analysts expect that Oncothyreon Inc . will post $-0.36 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray initiated coverage on shares of Oncothyreon Inc . in a research note to investors on Thursday, January 17th. They set an “underweight” rating and a $1.00 price target on the stock. Analysts at Wedbush downgraded shares of Oncothyreon Inc . from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, December 19th. They now have a $2.00 price target on the stock, down previously from $31.00.
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer.